TB500 (Thymosin B4 Acetate)

TB500 is a synthetic, acetylated peptide fragment (Ac-LKKTETQ, amino acids 17–23) of Thymosin Beta-4 (Tβ4)—a naturally occurring 43-amino-acid peptide ubiquitous in mammalian tissues. It retains the core actin-binding domain of full-length Tβ4 and is widely studied for potent regenerative, anti-inflammatory, angiogenic, and cytoprotective effects.
2mg*10vials $55 10mg*10vials $150
5mg*10vials $85

 

Product Information

Mechanism of Action (Detailed but Concise)

 
  1. Actin regulation (core mechanism)
    TB500 binds to G‑actin to maintain cytoskeletal flexibility, which supports faster migration of fibroblasts, endothelial cells, and stem cells to damaged tissue sites, enabling efficient repair initiation.
  2. Strong pro‑angiogenic effect
    It upregulates VEGF and supports endothelial cell proliferation and tube formation, boosting blood vessel growth to improve oxygen and nutrient supply to injured or poorly vascularized tissues.
  3. Potent anti‑inflammatory activity
    TB500 reduces key pro‑inflammatory cytokines including TNF‑α, IL‑1β, and IL‑6, while increasing anti‑inflammatory signals, thereby reducing swelling, pain, and secondary tissue injury.
  4. Enhanced tissue regeneration
    It promotes collagen remodeling, keratinocyte and muscle cell proliferation, and stem cell mobilization, leading to faster healing, better tissue structure, and reduced scar formation.
  5. Cytoprotective and anti‑apoptotic effects
    It protects cells from oxidative stress and ischemic damage, inhibits excessive cell death, and helps preserve tissue integrity and function during injury and recovery.

Important Warnings & Safety Considerations

 

Contraindications

  • Known hypersensitivity to TB500 or acetate excipients
  • Active or recurrent malignant disease (may enhance angiogenesis and cell migration)
  • Pregnancy, lactation, and pediatric use (no safety data)
  • Proliferative diabetic retinopathy (may promote pathological blood vessel growth)
  • Severe bleeding disorders or concurrent anticoagulant therapy

Precautions

  • May increase tissue healing rate; monitor acute injuries for over‑proliferation
  • Local injection‑site reactions may occur
  • Not intended for oral use; no oral bioavailability
  • Long‑term safety in humans remains incompletely characterized

Common Adverse Reactions

  • Temporary redness, itching, or mild pain at injection site
  • Transient fatigue or lethargy
  • Mild headache or flushing
  • Temporary muscle soreness (rare)

Associated Products

Related Experimental Studies